-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, April 2nd.
Recently, new progress has been made in the research and development of inhalants: Hengrui's salmeterol and ticasone powder inhalation has entered the administrative approval stage, and the healthy yuan formoterol fumarate inhalation aerosol has been approved for clinical use.
.
.
.
The latest data from Minai.
com shows that the market size of terminal inhalants in public hospitals in key provinces and cities will exceed 3.
5 billion yuan in 2020, and the growth rate will decline for the first time.
The rankings of TOP20 products have changed, and the three major products have risen against the trend, and domestic brands have performed well.
In terms of new product declaration, 117 inhalants (counted by the name of the drug + the name of the declared company) are reported for production under the new classification, and 16 (8 varieties) have been approved for production and deemed to have been reviewed; 20 varieties under review have no generic drugs yet After being approved, Chia Tai Tianqing, Sichuan Prime, and Changfeng Pharmaceutical all have exclusive applications for production; the first domestically produced Class 1 new drug was born, and 22 new drugs for inhalation are under development (8 are Class 1 new drugs).
Recently, new progress has been made in the research and development of inhalants: Hengrui's salmeterol and ticasone powder inhalation has entered the administrative approval stage, and the healthy yuan formoterol fumarate inhalation aerosol has been approved for clinical use.
.
.
.
The latest data from Minai.
com shows that the market size of terminal inhalants in public hospitals in key provinces and cities will exceed 3.
5 billion yuan in 2020, and the growth rate will decline for the first time.
The rankings of TOP20 products have changed, and the three major products have risen against the trend, and domestic brands have performed well.
In terms of new product declaration, 117 inhalants (counted by the name of the drug + the name of the declared company) are reported for production under the new classification, and 16 (8 varieties) have been approved for production and deemed to have been reviewed; 20 varieties under review have no generic drugs yet After being approved, Chia Tai Tianqing, Sichuan Prime, and Changfeng Pharmaceutical all have exclusive applications for production; the first domestically produced Class 1 new drug was born, and 22 new drugs for inhalation are under development (8 are Class 1 new drugs).
TOP20 inhalants released, three major products rose against the trend
According to data from Mi Nei.
com, the market size of terminal inhalants in public hospitals in key provinces and cities has expanded year by year, and the annual growth rate has remained at double digits.
Affected by the epidemic in 2020, the growth rate of inhalants dropped for the first time, and its market size exceeded 3.
5 billion yuan, a year-on-year decline of 15.
76%.
com, the market size of terminal inhalants in public hospitals in key provinces and cities has expanded year by year, and the annual growth rate has remained at double digits.
Affected by the epidemic in 2020, the growth rate of inhalants dropped for the first time, and its market size exceeded 3.
5 billion yuan, a year-on-year decline of 15.
76%.
Quarterly sales of terminal inhalants in public hospitals in key provinces and cities of Minai.
com (Unit: 100 million yuan)
com (Unit: 100 million yuan)
Source: The terminal competition pattern of public hospitals in key provinces and cities of Meinenet
In terms of quarterly sales, the sales of inhalants in Q4 in recent years are higher than those of other quarters, but overall it does not show very obvious seasonal characteristics.
In 2020, due to the outbreak of the new crown epidemic, the number of hospital consultations has decreased, so Q1 and Q2 sales have declined significantly.
As the epidemic is controlled and normalized, the inhalation market has recovered, and Q4 sales have basically returned to normal.
In 2020, due to the outbreak of the new crown epidemic, the number of hospital consultations has decreased, so Q1 and Q2 sales have declined significantly.
As the epidemic is controlled and normalized, the inhalation market has recovered, and Q4 sales have basically returned to normal.
The inhalation market is highly concentrated.
The total market share of TOP20 products exceeds 90%.
The TOP3 products, budesonide suspension for inhalation, sevoflurane for inhalation, and acetylcysteine solution for inhalation, account for "half of the country"; Product sales declined.
Acetylcysteine solution for inhalation, aerosol inhalation solution of salbutamol sulfate, and desflurane rose against the trend, among which acetylcysteine solution for inhalation increased by 36.
31%.
The total market share of TOP20 products exceeds 90%.
The TOP3 products, budesonide suspension for inhalation, sevoflurane for inhalation, and acetylcysteine solution for inhalation, account for "half of the country"; Product sales declined.
Acetylcysteine solution for inhalation, aerosol inhalation solution of salbutamol sulfate, and desflurane rose against the trend, among which acetylcysteine solution for inhalation increased by 36.
31%.
Judging from the ranking of TOP20 products, desflurane has increased significantly, up 4 places from last year; followed by salbutamol sulfate atomized inhalation solution and tiotropium bromide spray, both rising 3 places; propionic acid for inhalation The sales of beclomethasone suspension dropped significantly, dropping 4 places.
TOP10 terminal inhalants in public hospitals of key provinces and cities in Minai.
com
com
Source: The terminal competition pattern of public hospitals in key provinces and cities of Meinenet
From the perspective of brand rankings, 8 of the TOP20 brands are domestic brands, an increase of 1 over the same period last year, which is Chia Tai Tianqing’s budesonide suspension for inhalation; compared with 2019, the ranking of many domestic brands in 2020 has improved.
Among them, Hengrui Medicine's sevoflurane for inhalation ranked second, Hainan Star Pharmaceutical's acetylcysteine solution for inhalation rose by 58.
23%, ranking from 17th to 8th, and Shenzhen Dafo Pharmaceutical's salbutamol sulfate The growth rate of nebulized inhalation solution reached 33.
6%, up 5 places.
Among them, Hengrui Medicine's sevoflurane for inhalation ranked second, Hainan Star Pharmaceutical's acetylcysteine solution for inhalation rose by 58.
23%, ranking from 17th to 8th, and Shenzhen Dafo Pharmaceutical's salbutamol sulfate The growth rate of nebulized inhalation solution reached 33.
6%, up 5 places.
16 inhalants have been reviewed, Chia Tai Tianqing, Sichuan Prit.
.
.
the first imitation of the offensive
.
.
the first imitation of the offensive
On March 26, Hengrui Medicine’s salmeterol ticasone powder inhalation entered the administrative approval stage.
Currently, the product has not been approved for the first imitation; on March 22, Shisiyao’s terbutaline sulfate nebulized inhalation The solution and the Salbutamol sulfate solution for inhalation of Santos Medical have entered the administrative examination and approval stage.
The former has only one company's product reviewed, and the latter has been reviewed by four companies' products.
Currently, the product has not been approved for the first imitation; on March 22, Shisiyao’s terbutaline sulfate nebulized inhalation The solution and the Salbutamol sulfate solution for inhalation of Santos Medical have entered the administrative examination and approval stage.
The former has only one company's product reviewed, and the latter has been reviewed by four companies' products.
According to data from Meinenet.
com, as of March 31, 117 inhalants ( counted by the name of the drug + the name of the declared company) were reported for production under the new registration classification, of which 16 inhalants have been approved for production and deemed to have been reviewed, involving 8 A variety (in terms of drug name).
com, as of March 31, 117 inhalants ( counted by the name of the drug + the name of the declared company) were reported for production under the new registration classification, of which 16 inhalants have been approved for production and deemed to have been reviewed, involving 8 A variety (in terms of drug name).
Inhalants with 5 or more companies reporting the new classification
In terms of product competition, there are 5 or more companies reporting the production of the 9 new categories, including ambroxol hydrochloride inhalation solution (including ambroxol hydrochloride solution for inhalation, ambroxol hydrochloride inhalation solution for inhalation, and ammonia hydrochloride).
Bromoxol aerosol inhalation solution) competition is fierce, and 18 companies have applied for production under the new classification.
The products of Korean-American Medicine and Yunnan Longhai Natural Plant Medicine have been successfully evaluated.
Bromoxol aerosol inhalation solution) competition is fierce, and 18 companies have applied for production under the new classification.
The products of Korean-American Medicine and Yunnan Longhai Natural Plant Medicine have been successfully evaluated.
Companies reporting 3 or more inhalants under the new classification
Judging from the status of enterprise declarations, the number of inhalation products reported by 10 companies under the new classification is 3 or more.
Health yuan leads with 13 inhalants, 4 of which have been approved for production and deemed to have been evaluated; Sichuan Prime Medicine is followed by 12 inhalants, 3 of which have been approved for production and deemed to have been reviewed.
Health yuan leads with 13 inhalants, 4 of which have been approved for production and deemed to have been evaluated; Sichuan Prime Medicine is followed by 12 inhalants, 3 of which have been approved for production and deemed to have been reviewed.
Among the new classifications of inhalants that are still under review and approval, 20 of them have not been approved for the first imitation (including the first imitation of the dosage form), and 12 of them are reported for production under the new classification by the exclusive enterprise .
Sichuan Prime and Chia Tai Tianqing and Changfeng Pharmaceutical have three.
Sichuan Prime and Chia Tai Tianqing and Changfeng Pharmaceutical have three.
The new classification is under review and there is no first imitation inhalant
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The global sales of salmeterol ticasone, fluticasone vilanterol, and budesonide formoterol in 2020 will be 1.
535 billion pounds, 1.
124 billion pounds, and 2.
721 billion dollars, respectively.
Hengrui Medicine's salmeterol ticasone powder inhalation has recently entered the administrative examination and approval stage, can it successfully win the first copy? We will wait and see!
535 billion pounds, 1.
124 billion pounds, and 2.
721 billion dollars, respectively.
Hengrui Medicine's salmeterol ticasone powder inhalation has recently entered the administrative examination and approval stage, can it successfully win the first copy? We will wait and see!
The first class 1 new drug for inhalation was born, 22 new drugs are on the way
Recently, Joincare's new class 2 drug formoterol fumarate inhalation aerosol was approved clinically for the treatment of asthma and COPD.
Following the approval of the first category of new drug benzoquinium bromide nasal spray, according to incomplete statistics, there are currently 22 domestic new inhalants (excluding new indications for the development of new drugs on the market) at the clinical application and above stage.
8 models are Class 1 new drugs.
Following the approval of the first category of new drug benzoquinium bromide nasal spray, according to incomplete statistics, there are currently 22 domestic new inhalants (excluding new indications for the development of new drugs on the market) at the clinical application and above stage.
8 models are Class 1 new drugs.
In terms of indications, 22 new inhalation drugs are concentrated in the respiratory system (COPD, bronchiectasis, asthma, etc.
) and nervous system (depression, sedation, etc.
) in two therapeutic categories; from the perspective of research and development progress, 2 new drugs are currently under development.
In phase III clinical trials, 5 new class 1 drugs have entered or completed phase I clinical trials.
) and nervous system (depression, sedation, etc.
) in two therapeutic categories; from the perspective of research and development progress, 2 new drugs are currently under development.
In phase III clinical trials, 5 new class 1 drugs have entered or completed phase I clinical trials.
The status of inhalation of new domestic drugs in research
Source: China Drug Clinical Trial Publicity Library of Meinenet
In the field of respiratory system, Shenzhen Taitai Pharmaceutical's tobramycin inhalation solution (bronchiectasis) is undergoing phase III clinical trials, and is expected to become the first inhaled antibiotic drug in China; Chengdu Lisite Pharmaceutical's penehyclidine hydrochloride aerosol (Chronic obstructive pulmonary disease) has completed phase II clinical trials; Jiangsu Changtai Pharmaceutical’s sodium pyruvate inhalation (chronic obstructive pulmonary disease) has completed phase I clinical trials; Beijing Shuobai Pharmaceutical’s 101BHG-D01 inhalation aerosol ( Chronic Obstructive Pulmonary and Asthma) is undergoing phase I clinical trials, which is a new type of M3 receptor antagonist.
In the field of nervous system, Hengrui's dexmedetomidine hydrochloride nasal spray (preoperative sedation) is undergoing phase III clinical trials, and the hydrochloric acid (R)-ketamine nasal spray (depression) is undergoing phase I clinical trials; People's Liberation Army of China The midazolam nasal spray (long-term, acute, convulsive seizure) of the Institute of Toxicology and Medicine of the Academy of Military Medical Sciences completed Phase I clinical trial.
Source: Minet database
Note: According to the 2020 National Medical Insurance Catalogue, inhalants are divided into aerosols, powder mists, inhalants, inhalation powder mists, dry powder inhalants, powder inhalants, atomized solutions, inhalation aerosols, inhalation ( Solution, inhalation (used) suspension, (nasal) spray, nasal inhalation aerosol, atomized suspension for inhalation, inhalation (used) aerosol, atomized liquid.
Statistics are as of March 31.
If there are any omissions, please correct me!
Statistics are as of March 31.
If there are any omissions, please correct me!
Medical News, April 2nd.
Recently, new progress has been made in the research and development of inhalants: Hengrui's salmeterol and ticasone powder inhalation has entered the administrative approval stage, and the healthy yuan formoterol fumarate inhalation aerosol has been approved for clinical use.
.
.
.
The latest data from Minai.
com shows that the market size of terminal inhalants in public hospitals in key provinces and cities will exceed 3.
5 billion yuan in 2020, and the growth rate will decline for the first time.
The rankings of TOP20 products have changed, and the three major products have risen against the trend, and domestic brands have performed well.
In terms of new product declaration, 117 inhalants (counted by the name of the drug + the name of the declared company) are reported for production under the new classification, and 16 (8 varieties) have been approved for production and deemed to have been reviewed; 20 varieties under review have no generic drugs yet After being approved, Chia Tai Tianqing, Sichuan Prime, and Changfeng Pharmaceutical all have exclusive applications for production; the first domestically produced Class 1 new drug was born, and 22 new drugs for inhalation are under development (8 are Class 1 new drugs).
Recently, new progress has been made in the research and development of inhalants: Hengrui's salmeterol and ticasone powder inhalation has entered the administrative approval stage, and the healthy yuan formoterol fumarate inhalation aerosol has been approved for clinical use.
.
.
.
The latest data from Minai.
com shows that the market size of terminal inhalants in public hospitals in key provinces and cities will exceed 3.
5 billion yuan in 2020, and the growth rate will decline for the first time.
The rankings of TOP20 products have changed, and the three major products have risen against the trend, and domestic brands have performed well.
In terms of new product declaration, 117 inhalants (counted by the name of the drug + the name of the declared company) are reported for production under the new classification, and 16 (8 varieties) have been approved for production and deemed to have been reviewed; 20 varieties under review have no generic drugs yet After being approved, Chia Tai Tianqing, Sichuan Prime, and Changfeng Pharmaceutical all have exclusive applications for production; the first domestically produced Class 1 new drug was born, and 22 new drugs for inhalation are under development (8 are Class 1 new drugs).
TOP20 inhalants released, three major products rose against the trend
According to data from Mi Nei.
com, the market size of terminal inhalants in public hospitals in key provinces and cities has expanded year by year, and the annual growth rate has remained at double digits.
Affected by the epidemic in 2020, the growth rate of inhalants dropped for the first time, and its market size exceeded 3.
5 billion yuan, a year-on-year decline of 15.
76%.
com, the market size of terminal inhalants in public hospitals in key provinces and cities has expanded year by year, and the annual growth rate has remained at double digits.
Affected by the epidemic in 2020, the growth rate of inhalants dropped for the first time, and its market size exceeded 3.
5 billion yuan, a year-on-year decline of 15.
76%.
Quarterly sales of terminal inhalants in public hospitals in key provinces and cities of Minai.
com (Unit: 100 million yuan)
com (Unit: 100 million yuan)
Source: The terminal competition pattern of public hospitals in key provinces and cities of Meinenet
In terms of quarterly sales, the sales of inhalants in Q4 in recent years are higher than those of other quarters, but overall it does not show very obvious seasonal characteristics.
In 2020, due to the outbreak of the new crown epidemic, the number of hospital consultations has decreased, so Q1 and Q2 sales have declined significantly.
As the epidemic is controlled and normalized, the inhalation market has recovered, and Q4 sales have basically returned to normal.
In 2020, due to the outbreak of the new crown epidemic, the number of hospital consultations has decreased, so Q1 and Q2 sales have declined significantly.
As the epidemic is controlled and normalized, the inhalation market has recovered, and Q4 sales have basically returned to normal.
The inhalation market is highly concentrated.
The total market share of TOP20 products exceeds 90%.
The TOP3 products, budesonide suspension for inhalation, sevoflurane for inhalation, and acetylcysteine solution for inhalation, account for "half of the country"; Product sales declined.
Acetylcysteine solution for inhalation, aerosol inhalation solution of salbutamol sulfate, and desflurane rose against the trend, among which acetylcysteine solution for inhalation increased by 36.
31%.
The total market share of TOP20 products exceeds 90%.
The TOP3 products, budesonide suspension for inhalation, sevoflurane for inhalation, and acetylcysteine solution for inhalation, account for "half of the country"; Product sales declined.
Acetylcysteine solution for inhalation, aerosol inhalation solution of salbutamol sulfate, and desflurane rose against the trend, among which acetylcysteine solution for inhalation increased by 36.
31%.
Judging from the ranking of TOP20 products, desflurane has increased significantly, up 4 places from last year; followed by salbutamol sulfate atomized inhalation solution and tiotropium bromide spray, both rising 3 places; propionic acid for inhalation The sales of beclomethasone suspension dropped significantly, dropping 4 places.
TOP10 terminal inhalants in public hospitals of key provinces and cities in Minai.
com
com
Source: The terminal competition pattern of public hospitals in key provinces and cities of Meinenet
From the perspective of brand rankings, 8 of the TOP20 brands are domestic brands, an increase of 1 over the same period last year, which is Chia Tai Tianqing’s budesonide suspension for inhalation; compared with 2019, the ranking of many domestic brands in 2020 has improved.
Among them, Hengrui Medicine's sevoflurane for inhalation ranked second, Hainan Star Pharmaceutical's acetylcysteine solution for inhalation rose by 58.
23%, ranking from 17th to 8th, and Shenzhen Dafo Pharmaceutical's salbutamol sulfate The growth rate of nebulized inhalation solution reached 33.
6%, up 5 places.
Among them, Hengrui Medicine's sevoflurane for inhalation ranked second, Hainan Star Pharmaceutical's acetylcysteine solution for inhalation rose by 58.
23%, ranking from 17th to 8th, and Shenzhen Dafo Pharmaceutical's salbutamol sulfate The growth rate of nebulized inhalation solution reached 33.
6%, up 5 places.
16 inhalants have been reviewed, Chia Tai Tianqing, Sichuan Prit.
.
.
the first imitation of the offensive
.
.
the first imitation of the offensive
On March 26, Hengrui Medicine’s salmeterol ticasone powder inhalation entered the administrative approval stage.
Currently, the product has not been approved for the first imitation; on March 22, Shisiyao’s terbutaline sulfate nebulized inhalation The solution and the Salbutamol sulfate solution for inhalation of Santos Medical have entered the administrative examination and approval stage.
The former has only one company's product reviewed, and the latter has been reviewed by four companies' products.
Currently, the product has not been approved for the first imitation; on March 22, Shisiyao’s terbutaline sulfate nebulized inhalation The solution and the Salbutamol sulfate solution for inhalation of Santos Medical have entered the administrative examination and approval stage.
The former has only one company's product reviewed, and the latter has been reviewed by four companies' products.
According to data from Meinenet.
com, as of March 31, 117 inhalants ( counted by the name of the drug + the name of the declared company) were reported for production under the new registration classification, of which 16 inhalants have been approved for production and deemed to have been reviewed, involving 8 A variety (in terms of drug name).
com, as of March 31, 117 inhalants ( counted by the name of the drug + the name of the declared company) were reported for production under the new registration classification, of which 16 inhalants have been approved for production and deemed to have been reviewed, involving 8 A variety (in terms of drug name).
Inhalants with 5 or more companies reporting the new classification
In terms of product competition, there are 5 or more companies reporting the production of the 9 new categories, including ambroxol hydrochloride inhalation solution (including ambroxol hydrochloride solution for inhalation, ambroxol hydrochloride inhalation solution for inhalation, and ammonia hydrochloride).
Bromoxol aerosol inhalation solution) competition is fierce, and 18 companies have applied for production under the new classification.
The products of Korean-American Medicine and Yunnan Longhai Natural Plant Medicine have been successfully evaluated.
Bromoxol aerosol inhalation solution) competition is fierce, and 18 companies have applied for production under the new classification.
The products of Korean-American Medicine and Yunnan Longhai Natural Plant Medicine have been successfully evaluated.
Companies reporting 3 or more inhalants under the new classification
Judging from the status of enterprise declarations, the number of inhalation products reported by 10 companies under the new classification is 3 or more.
Health yuan leads with 13 inhalants, 4 of which have been approved for production and deemed to have been evaluated; Sichuan Prime Medicine is followed by 12 inhalants, 3 of which have been approved for production and deemed to have been reviewed.
Health yuan leads with 13 inhalants, 4 of which have been approved for production and deemed to have been evaluated; Sichuan Prime Medicine is followed by 12 inhalants, 3 of which have been approved for production and deemed to have been reviewed.
Among the new classifications of inhalants that are still under review and approval, 20 of them have not been approved for the first imitation (including the first imitation of the dosage form), and 12 of them are reported for production under the new classification by the exclusive enterprise .
Sichuan Prime and Chia Tai Tianqing and Changfeng Pharmaceutical have three.
Sichuan Prime and Chia Tai Tianqing and Changfeng Pharmaceutical have three.
The new classification is under review and there is no first imitation inhalant
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The global sales of salmeterol ticasone, fluticasone vilanterol, and budesonide formoterol in 2020 will be 1.
535 billion pounds, 1.
124 billion pounds, and 2.
721 billion dollars, respectively.
Hengrui Medicine's salmeterol ticasone powder inhalation has recently entered the administrative examination and approval stage, can it successfully win the first copy? We will wait and see!
535 billion pounds, 1.
124 billion pounds, and 2.
721 billion dollars, respectively.
Hengrui Medicine's salmeterol ticasone powder inhalation has recently entered the administrative examination and approval stage, can it successfully win the first copy? We will wait and see!
The first class 1 new drug for inhalation was born, 22 new drugs are on the way
Recently, Joincare's new class 2 drug formoterol fumarate inhalation aerosol was approved clinically for the treatment of asthma and COPD.
Following the approval of the first category of new drug benzoquinium bromide nasal spray, according to incomplete statistics, there are currently 22 domestic new inhalants (excluding new indications for the development of new drugs on the market) at the clinical application and above stage.
8 models are Class 1 new drugs.
Following the approval of the first category of new drug benzoquinium bromide nasal spray, according to incomplete statistics, there are currently 22 domestic new inhalants (excluding new indications for the development of new drugs on the market) at the clinical application and above stage.
8 models are Class 1 new drugs.
In terms of indications, 22 new inhalation drugs are concentrated in the respiratory system (COPD, bronchiectasis, asthma, etc.
) and nervous system (depression, sedation, etc.
) in two therapeutic categories; from the perspective of research and development progress, 2 new drugs are currently under development.
In phase III clinical trials, 5 new class 1 drugs have entered or completed phase I clinical trials.
) and nervous system (depression, sedation, etc.
) in two therapeutic categories; from the perspective of research and development progress, 2 new drugs are currently under development.
In phase III clinical trials, 5 new class 1 drugs have entered or completed phase I clinical trials.
The status of inhalation of new domestic drugs in research
Source: China Drug Clinical Trial Publicity Library of Meinenet
In the field of respiratory system, Shenzhen Taitai Pharmaceutical's tobramycin inhalation solution (bronchiectasis) is undergoing phase III clinical trials, and is expected to become the first inhaled antibiotic drug in China; Chengdu Lisite Pharmaceutical's penehyclidine hydrochloride aerosol (Chronic obstructive pulmonary disease) has completed phase II clinical trials; Jiangsu Changtai Pharmaceutical’s sodium pyruvate inhalation (chronic obstructive pulmonary disease) has completed phase I clinical trials; Beijing Shuobai Pharmaceutical’s 101BHG-D01 inhalation aerosol ( Chronic Obstructive Pulmonary and Asthma) is undergoing phase I clinical trials, which is a new type of M3 receptor antagonist.
In the field of nervous system, Hengrui's dexmedetomidine hydrochloride nasal spray (preoperative sedation) is undergoing phase III clinical trials, and the hydrochloric acid (R)-ketamine nasal spray (depression) is undergoing phase I clinical trials; People's Liberation Army of China The midazolam nasal spray (long-term, acute, convulsive seizure) of the Institute of Toxicology and Medicine of the Academy of Military Medical Sciences completed Phase I clinical trial.
Source: Minet database
Note: According to the 2020 National Medical Insurance Catalogue, inhalants are divided into aerosols, powder mists, inhalants, inhalation powder mists, dry powder inhalants, powder inhalants, atomized solutions, inhalation aerosols, inhalation ( Solution, inhalation (used) suspension, (nasal) spray, nasal inhalation aerosol, atomized suspension for inhalation, inhalation (used) aerosol, atomized liquid.
Statistics are as of March 31.
If there are any omissions, please correct me!
Statistics are as of March 31.
If there are any omissions, please correct me!
Medical News, April 2nd.
Recently, new progress has been made in the research and development of inhalants: Hengrui's salmeterol and ticasone powder inhalation has entered the administrative approval stage, and the healthy yuan formoterol fumarate inhalation aerosol has been approved for clinical use.
.
.
.
The latest data from Minai.
com shows that the market size of terminal inhalants in public hospitals in key provinces and cities will exceed 3.
5 billion yuan in 2020, and the growth rate will decline for the first time.
The rankings of TOP20 products have changed, and the three major products have risen against the trend, and domestic brands have performed well.
In terms of new product declaration, 117 inhalants (counted by the name of the drug + the name of the declared company) are reported for production under the new classification, and 16 (8 varieties) have been approved for production and deemed to have been reviewed; 20 varieties under review have no generic drugs yet After being approved, Chia Tai Tianqing, Sichuan Prime, and Changfeng Pharmaceutical all have exclusive applications for production; the first domestically produced Class 1 new drug was born, and 22 new drugs for inhalation are under development (8 are Class 1 new drugs).
Recently, new progress has been made in the research and development of inhalants: Hengrui's salmeterol and ticasone powder inhalation has entered the administrative approval stage, and the healthy yuan formoterol fumarate inhalation aerosol has been approved for clinical use.
.
.
.
The latest data from Minai.
com shows that the market size of terminal inhalants in public hospitals in key provinces and cities will exceed 3.
5 billion yuan in 2020, and the growth rate will decline for the first time.
The rankings of TOP20 products have changed, and the three major products have risen against the trend, and domestic brands have performed well.
In terms of new product declaration, 117 inhalants (counted by the name of the drug + the name of the declared company) are reported for production under the new classification, and 16 (8 varieties) have been approved for production and deemed to have been reviewed; 20 varieties under review have no generic drugs yet After being approved, Chia Tai Tianqing, Sichuan Prime, and Changfeng Pharmaceutical all have exclusive applications for production; the first domestically produced Class 1 new drug was born, and 22 new drugs for inhalation are under development (8 are Class 1 new drugs).
TOP20 inhalants released, three major products rose against the trend
TOP20 inhalants released, three major products rose against the trend According to data from Mi Nei.
com, the market size of terminal inhalants in public hospitals in key provinces and cities has expanded year by year, and the annual growth rate has remained at double digits.
Affected by the epidemic in 2020, the growth rate of inhalants dropped for the first time, and its market size exceeded 3.
5 billion yuan, a year-on-year decline of 15.
76%.
Hospital hospital hospitalcom, the market size of terminal inhalants in public hospitals in key provinces and cities has expanded year by year, and the annual growth rate has remained at double digits.
Affected by the epidemic in 2020, the growth rate of inhalants dropped for the first time, and its market size exceeded 3.
5 billion yuan, a year-on-year decline of 15.
76%.
Quarterly sales of terminal inhalants in public hospitals in key provinces and cities of Minai.
com (Unit: 100 million yuan)
com (Unit: 100 million yuan)
Source: The terminal competition pattern of public hospitals in key provinces and cities of Meinenet
In terms of quarterly sales, the sales of inhalants in Q4 in recent years are higher than those of other quarters, but overall it does not show very obvious seasonal characteristics.
In 2020, due to the outbreak of the new crown epidemic, the number of hospital consultations has decreased, so Q1 and Q2 sales have declined significantly.
As the epidemic is controlled and normalized, the inhalation market has recovered, and Q4 sales have basically returned to normal.
In 2020, due to the outbreak of the new crown epidemic, the number of hospital consultations has decreased, so Q1 and Q2 sales have declined significantly.
As the epidemic is controlled and normalized, the inhalation market has recovered, and Q4 sales have basically returned to normal.
The inhalation market is highly concentrated.
The total market share of TOP20 products exceeds 90%.
The TOP3 products, budesonide suspension for inhalation, sevoflurane for inhalation, and acetylcysteine solution for inhalation, account for "half of the country"; Product sales declined.
Acetylcysteine solution for inhalation, aerosol inhalation solution of salbutamol sulfate, and desflurane rose against the trend, among which acetylcysteine solution for inhalation increased by 36.
31%.
The total market share of TOP20 products exceeds 90%.
The TOP3 products, budesonide suspension for inhalation, sevoflurane for inhalation, and acetylcysteine solution for inhalation, account for "half of the country"; Product sales declined.
Acetylcysteine solution for inhalation, aerosol inhalation solution of salbutamol sulfate, and desflurane rose against the trend, among which acetylcysteine solution for inhalation increased by 36.
31%.
Judging from the ranking of TOP20 products, desflurane has increased significantly, up 4 places from last year; followed by salbutamol sulfate atomized inhalation solution and tiotropium bromide spray, both rising 3 places; propionic acid for inhalation The sales of beclomethasone suspension dropped significantly, dropping 4 places.
TOP10 terminal inhalants in public hospitals of key provinces and cities in Minai.
com
com
Source: The terminal competition pattern of public hospitals in key provinces and cities of Meinenet
From the perspective of brand rankings, 8 of the TOP20 brands are domestic brands, an increase of 1 over the same period last year, which is Chia Tai Tianqing’s budesonide suspension for inhalation; compared with 2019, the ranking of many domestic brands in 2020 has improved.
Among them, Hengrui Medicine's sevoflurane for inhalation ranked second, Hainan Star Pharmaceutical's acetylcysteine solution for inhalation rose by 58.
23%, ranking from 17th to 8th, and Shenzhen Dafo Pharmaceutical's salbutamol sulfate The growth rate of nebulized inhalation solution reached 33.
6%, up 5 places.
Among them, Hengrui Medicine's sevoflurane for inhalation ranked second, Hainan Star Pharmaceutical's acetylcysteine solution for inhalation rose by 58.
23%, ranking from 17th to 8th, and Shenzhen Dafo Pharmaceutical's salbutamol sulfate The growth rate of nebulized inhalation solution reached 33.
6%, up 5 places.
16 inhalants have been reviewed, Chia Tai Tianqing, Sichuan Prit.
.
.
the first imitation of the offensive
16 inhalants have been reviewed, Chia Tai Tianqing, Sichuan Prit. .
.
the first imitation of the offensive
.
.
the first imitation of the offensive
On March 26, Hengrui Medicine’s salmeterol ticasone powder inhalation entered the administrative approval stage.
Currently, the product has not been approved for the first imitation; on March 22, Shisiyao’s terbutaline sulfate nebulized inhalation The solution and the Salbutamol sulfate solution for inhalation of Santos Medical have entered the administrative examination and approval stage.
The former has only one company's product reviewed, and the latter has been reviewed by four companies' products.
Currently, the product has not been approved for the first imitation; on March 22, Shisiyao’s terbutaline sulfate nebulized inhalation The solution and the Salbutamol sulfate solution for inhalation of Santos Medical have entered the administrative examination and approval stage.
The former has only one company's product reviewed, and the latter has been reviewed by four companies' products.
According to data from Meinenet.
com, as of March 31, 117 inhalants ( counted by the name of the drug + the name of the declared company) were reported for production under the new registration classification, of which 16 inhalants have been approved for production and deemed to have been reviewed, involving 8 A variety (in terms of drug name).
Medicine, medicine, medicinecom, as of March 31, 117 inhalants ( counted by the name of the drug + the name of the declared company) were reported for production under the new registration classification, of which 16 inhalants have been approved for production and deemed to have been reviewed, involving 8 A variety (in terms of drug name).
Inhalants with 5 or more companies reporting the new classification
In terms of product competition, there are 5 or more companies reporting the production of the 9 new categories, including ambroxol hydrochloride inhalation solution (including ambroxol hydrochloride solution for inhalation, ambroxol hydrochloride inhalation solution for inhalation, and ammonia hydrochloride).
Bromoxol aerosol inhalation solution) competition is fierce, and 18 companies have applied for production under the new classification.
The products of Korean-American Medicine and Yunnan Longhai Natural Plant Medicine have been successfully evaluated.
Bromoxol aerosol inhalation solution) competition is fierce, and 18 companies have applied for production under the new classification.
The products of Korean-American Medicine and Yunnan Longhai Natural Plant Medicine have been successfully evaluated.
Companies reporting 3 or more inhalants under the new classification
Judging from the status of enterprise declarations, the number of inhalation products reported by 10 companies under the new classification is 3 or more.
Health yuan leads with 13 inhalants, 4 of which have been approved for production and deemed to have been evaluated; Sichuan Prime Medicine is followed by 12 inhalants, 3 of which have been approved for production and deemed to have been reviewed.
Health health health medicine medicine medicineHealth yuan leads with 13 inhalants, 4 of which have been approved for production and deemed to have been evaluated; Sichuan Prime Medicine is followed by 12 inhalants, 3 of which have been approved for production and deemed to have been reviewed.
Among the new classifications of inhalants that are still under review and approval, 20 of them have not been approved for the first imitation (including the first imitation of the dosage form), and 12 of them are reported for production under the new classification by the exclusive enterprise .
Sichuan Prime and Chia Tai Tianqing and Changfeng Pharmaceutical have three.
Enterprise business enterpriseSichuan Prime and Chia Tai Tianqing and Changfeng Pharmaceutical have three.
The new classification is under review and there is no first imitation inhalant
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The global sales of salmeterol ticasone, fluticasone vilanterol, and budesonide formoterol in 2020 will be 1.
535 billion pounds, 1.
124 billion pounds, and 2.
721 billion dollars, respectively.
Hengrui Medicine's salmeterol ticasone powder inhalation has recently entered the administrative examination and approval stage, can it successfully win the first copy? We will wait and see!
535 billion pounds, 1.
124 billion pounds, and 2.
721 billion dollars, respectively.
Hengrui Medicine's salmeterol ticasone powder inhalation has recently entered the administrative examination and approval stage, can it successfully win the first copy? We will wait and see!
The first class 1 new drug for inhalation was born, 22 new drugs are on the way
The first class 1 new drug for inhalation was born, 22 new drugs are on the way Recently, Joincare's new class 2 drug formoterol fumarate inhalation aerosol was approved clinically for the treatment of asthma and COPD.
Following the approval of the first category of new drug benzoquinium bromide nasal spray, according to incomplete statistics, there are currently 22 domestic new inhalants (excluding new indications for the development of new drugs on the market) at the clinical application and above stage.
8 models are Class 1 new drugs.
Following the approval of the first category of new drug benzoquinium bromide nasal spray, according to incomplete statistics, there are currently 22 domestic new inhalants (excluding new indications for the development of new drugs on the market) at the clinical application and above stage.
8 models are Class 1 new drugs.
In terms of indications, 22 new inhalation drugs are concentrated in the respiratory system (COPD, bronchiectasis, asthma, etc.
) and nervous system (depression, sedation, etc.
) in two therapeutic categories; from the perspective of research and development progress, 2 new drugs are currently under development.
In phase III clinical trials, 5 new class 1 drugs have entered or completed phase I clinical trials.
) and nervous system (depression, sedation, etc.
) in two therapeutic categories; from the perspective of research and development progress, 2 new drugs are currently under development.
In phase III clinical trials, 5 new class 1 drugs have entered or completed phase I clinical trials.
The status of inhalation of new domestic drugs in research
Source: China Drug Clinical Trial Publicity Library of Meinenet
In the field of respiratory system, Shenzhen Taitai Pharmaceutical's tobramycin inhalation solution (bronchiectasis) is undergoing phase III clinical trials, and is expected to become the first inhaled antibiotic drug in China; Chengdu Lisite Pharmaceutical's penehyclidine hydrochloride aerosol (Chronic obstructive pulmonary disease) has completed phase II clinical trials; Jiangsu Changtai Pharmaceutical’s sodium pyruvate inhalation (chronic obstructive pulmonary disease) has completed phase I clinical trials; Beijing Shuobai Pharmaceutical’s 101BHG-D01 inhalation aerosol ( Chronic Obstructive Pulmonary and Asthma) is undergoing phase I clinical trials, which is a new type of M3 receptor antagonist.
In the field of nervous system, Hengrui's dexmedetomidine hydrochloride nasal spray (preoperative sedation) is undergoing phase III clinical trials, and the hydrochloric acid (R)-ketamine nasal spray (depression) is undergoing phase I clinical trials; People's Liberation Army of China The midazolam nasal spray (long-term, acute, convulsive seizure) of the Institute of Toxicology and Medicine of the Academy of Military Medical Sciences completed Phase I clinical trial.
Source: Minet database
Source: Minet database Note: According to the 2020 National Medical Insurance Catalogue, inhalants are divided into aerosols, powder mists, inhalants, inhalation powder mists, dry powder inhalants, powder inhalants, atomized solutions, inhalation aerosols, inhalation ( Solution, inhalation (used) suspension, (nasal) spray, nasal inhalation aerosol, atomized suspension for inhalation, inhalation (used) aerosol, atomized liquid.
Statistics are as of March 31.
If there are any omissions, please correct me!
Statistics are as of March 31.
If there are any omissions, please correct me!
